Bastida Jose Maria, González-Porras Jose Ramon, Jiménez Cristina, Benito Rocio, Ordoñez Gonzalo R, Álvarez-Román Maria Teresa, Fontecha M Elena, Janusz Kamila, Castillo David, Fisac Rosa María, García-Frade Luis Javier, Aguilar Carlos, Martínez María Paz, Bermejo Nuria, Herrero Sonia, Balanzategui Ana, Martin-Antorán Jose Manuel, Ramos Rafael, Cebeiro Maria Jose, Pardal Emilia, Aguilera Carmen, Pérez-Gutierrez Belen, Prieto Manuel, Riesco Susana, Mendoza Maria Carmen, Benito Ana, Hortal Benito-Sendin Ana, Jiménez-Yuste Víctor, Hernández-Rivas Jesus Maria, García-Sanz Ramon, González-Díaz Marcos, Sarasquete Maria Eugenia
José María Bastida Bermejo, Unidad de Hemostasia y Trombosis, Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, Paseo de San Vicente 58-182, 37007 Salamanca, Spain, E-mail:
Thromb Haemost. 2017 Jan 5;117(1):66-74. doi: 10.1160/TH16-05-0375. Epub 2016 Oct 13.
Currently, molecular diagnosis of haemophilia A and B (HA and HB) highlights the excess risk-inhibitor development associated with specific mutations, and enables carrier testing of female relatives and prenatal or preimplantation genetic diagnosis. Molecular testing for HA also helps distinguish it from von Willebrand disease (VWD). Next-generation sequencing (NGS) allows simultaneous investigation of several complete genes, even though they may span very extensive regions. This study aimed to evaluate the usefulness of a molecular algorithm employing an NGS approach for sequencing the complete F8, F9 and VWF genes. The proposed algorithm includes the detection of inversions of introns 1 and 22, an NGS custom panel (the entire F8, F9 and VWF genes), and multiplex ligation-dependent probe amplification (MLPA) analysis. A total of 102 samples (97 FVIII- and FIX-deficient patients, and five female carriers) were studied. IVS-22 screening identified 11 out of 20 severe HA patients and one female carrier. IVS-1 analysis did not reveal any alterations. The NGS approach gave positive results in 88 cases, allowing the differential diagnosis of mild/moderate HA and VWD in eight cases. MLPA confirmed one large exon deletion. Only one case did have no pathogenic variants. The proposed algorithm had an overall success rate of 99 %. In conclusion, our evaluation demonstrates that this algorithm can reliably identify pathogenic variants and diagnose patients with HA, HB or VWD.
目前,甲型和乙型血友病(HA和HB)的分子诊断突出了与特定突变相关的抑制物形成的额外风险,并能够对女性亲属进行携带者检测以及进行产前或植入前基因诊断。HA的分子检测也有助于将其与血管性血友病(VWD)区分开来。下一代测序(NGS)允许同时对几个完整基因进行检测,即使它们可能跨越非常广泛的区域。本研究旨在评估一种采用NGS方法对完整的F8、F9和VWF基因进行测序的分子算法的实用性。所提出的算法包括检测内含子1和22的倒位、一个NGS定制面板(完整的F8、F9和VWF基因)以及多重连接依赖探针扩增(MLPA)分析。共研究了102个样本(97例FVIII和FIX缺乏患者以及5例女性携带者)。IVS-22筛查在20例严重HA患者中鉴定出11例,以及1例女性携带者。IVS-1分析未发现任何改变。NGS方法在88例中得出阳性结果,在8例中实现了轻度/中度HA和VWD的鉴别诊断。MLPA证实了1例大的外显子缺失。仅1例未发现致病变异。所提出的算法总体成功率为99%。总之,我们的评估表明该算法能够可靠地识别致病变异并诊断HA、HB或VWD患者。